BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weiskirchen R, Tacke F. The Role of Radiologic Modalities in Diagnosing Nonalcoholic Steatohepatitis (NASH) and Fibrosis. Curr Hepatology Rep 2018;17:324-35. [DOI: 10.1007/s11901-018-0421-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Tacke F, Boeker KHW, Klinker H, Heyne R, Buggisch P, Pathil A, Wiegand J, Cornberg M, Lange C, Berg T, Zeuzem S, Mauss S. Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs. Liver Int 2020;40:539-48. [PMID: 31241820 DOI: 10.1111/liv.14186] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
2 Connolly JC, Lim JK. Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice. Curr Hepatology Rep 2019;18:249-58. [DOI: 10.1007/s11901-019-00471-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
3 Ogawa E, Takayama K, Hiramine S, Hayashi T, Toyoda K. Association between steatohepatitis biomarkers and hepatocellular carcinoma after hepatitis C elimination. Aliment Pharmacol Ther 2020;52:866-76. [DOI: 10.1111/apt.15976] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
4 Meurer SK, Karsdal MA, Weiskirchen R. Advances in the clinical use of collagen as biomarker of liver fibrosis. Expert Rev Mol Diagn 2020;20:947-69. [PMID: 32865433 DOI: 10.1080/14737159.2020.1814746] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]